Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary,
colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine
immune-conditioning. LOAd703 is administered by intratumoral image-guided injections. Maximum
50 patients can be enrolled.
LOAd703 is an immunostimulatory gene therapy using an selection replication competent
adenovirus as a gene vehicle. The virus is derived from serotype 5 adenovirus with the fiber
from serotype 35. It expresses the transgenes trimerized membrane-bound isoleucine zipper
(TMZ) TMZ-CD40L and 41BBL under control of a cytomegalovirus (CMV) promoter.